Last reviewed · How we verify
Fibrinogen/thrombin-coated collagen patch
A collagen patch coated with fibrinogen and thrombin that promotes hemostasis by providing a scaffold for clot formation and delivering clotting factors directly to the wound site.
A collagen patch coated with fibrinogen and thrombin that promotes hemostasis by providing a scaffold for clot formation and delivering clotting factors directly to the wound site. Used for Surgical hemostasis and bleeding control during surgical procedures.
At a glance
| Generic name | Fibrinogen/thrombin-coated collagen patch |
|---|---|
| Also known as | TachoSil® |
| Sponsor | Asan Medical Center |
| Drug class | Hemostatic agent / Surgical sealant |
| Modality | Small molecule |
| Therapeutic area | Surgery / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
The patch combines a collagen matrix with fibrinogen and thrombin to accelerate blood coagulation and hemostasis at surgical sites. Thrombin converts fibrinogen to fibrin, which polymerizes to form a stable clot, while the collagen provides structural support and enhances platelet adhesion and aggregation. This combination creates a localized hemostatic environment that reduces bleeding and promotes wound healing.
Approved indications
- Surgical hemostasis and bleeding control during surgical procedures
Common side effects
- Infection at surgical site
- Allergic reaction
- Inflammation
Key clinical trials
- GATT-Patch Versus TachoSil in Liver Surgery (NA)
- A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery (PHASE1, PHASE2)
- Neoveil® Versus TachoSil® for the Treatment of Pulmonary Air Leaks Following Lung Operation (NA)
- Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer (PHASE3)
- The Fibrin Pad Cardiovascular Study (PHASE2)
- The Effect of Application of TachoSil® in Pancreatoduodenectomy (PHASE4)
- The Fibrin Pad CV Phase III Study (PHASE3)
- Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: